Ovulation inducing drugs and ovarian cancer risk results from an extended followup of a large United States infertility cohort

Our findings were generally reassuring in not confirming a link between ovulation-inducing drugs and ovarian cancer; risk was increased, however, among women who, despite having used clomiphene citrate, remained nulligravid.

Like Comment

Authors

Britton Trabert, Ph.D., Emmet J. Lamb, M.D., Bert Scoccia, M.D., Kamran S. Moghissi, M.D., Carolyn L. Westhoff, M.D., Shelley Niwa, Louise A. Brinton, Ph.D.

Volume 100, Issue 6, Pages 1660-1666, December 2013

Abstract

Objective:

To examine the relationship of ovulation-inducing drugs and ovarian cancer.

Design:

Retrospective cohort study, with additional follow-up since initial report.

Setting:

Five large reproductive endocrinology practices.

Patient(s):

In a retrospective cohort of 9,825 women evaluated for infertility at five clinical sites in the United States between 1965 and 1988 with follow-up through 2010, we examined the relationship of ovulation-inducing drugs and ovarian cancer (n = 85).

Intervention(s):

None.

Main Outcome Measure(s):

Hazard rate ratios (RR) and 95% confidence intervals (CI) for ovarian cancer.

Result(s):

Among women evaluated for infertility, there was no association of ovarian cancer risk with ever use of clomiphene citrate (CC) (adjusted RR 1.34, 95% CI 0.86–2.07) or gonadotropins (RR 1.00, 95% CI 0.48–2.08) and no evidence that any of several more detailed subgroups of usage were related to an increased risk with one exception: women who used CC and remained nulligravid did demonstrate much higher risks than those who successfully conceived compared with nonusers (respectively, RR 3.63, 95% CI 1.36–9.72 vs. RR 0.88, 95% CI 0.47–1.63).

Conclusion(s):

Our overall results were reassuring and consistent with other studies. A reason for an association between CC use and ovarian cancer among persistently nulligravid women remains to be determined. Given the large and increasing number of women treated with ovulation-inducing drugs, the increased risk of ovarian cancer among the subset of women who remained nulligravid should be further monitored.

Read the full text at: http://www.fertstert.org/article/S0015-0282(13)02953-1/fulltext


Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.